Taysha Gene Therapies, Inc. Research And Development Expense

Quick Answer

Taysha Gene Therapies, Inc. reported Research And Development Expense of $86.40 million for the year ending 2025.

  • Taysha Gene Therapies, Inc. showed an increase of +30.9% in Research And Development Expense from 2024 to 2025.
  • This data is from Taysha Gene Therapies, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
  • XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 6 years of available data (2020 to 2025), Taysha Gene Therapies, Inc.'s Research And Development Expense has grown by 170.9%.
  • Historical annual values: Fiscal year 2025: $86.40 million | Fiscal year 2024: $66.00 million | Fiscal year 2023: $56.78 million | Fiscal year 2022: $91.17 million | Fiscal year 2021: $131.94 million | Fiscal year 2020: $31.89 million.
  • Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: